Every article, presentation, spotlight, and news item we've tagged to Men's Health.
Showing 1–10 of 10
Prostate-specific antigen (PSA) screening remains an underutilized tool for early prostate cancer detection despite proven capacity to identify disease at more treatable stages. The clinical evidence supports selective screening in men at appropriate risk, yet implementation barriers persist in clinical practice.
Melatonin restores testosterone production in aging Leydig cells by addressing oxidative stress and mitochondrial dysfunction, offering a mechanism-based alternative to passive testosterone supplementation. This shift from symptom management to cellular repair has implications for age-related hormonal decline in men.
Benign prostatic hyperplasia drug development has stagnated over 25 years, with clinical trial pipelines showing minimal innovation and priorities misaligned with patient burden. This stagnation reflects a broader market failure in addressing age-related conditions that affect quality of life and functional independence in aging populations.
Current PSA-based prostate cancer screening protocols miss clinically significant cancers and fail to distinguish aggressive from indolent disease, reducing detection effectiveness. Modern biomarkers and imaging technologies enable earlier identification of aggressive tumors when intervention is most effective, fundamentally altering outcomes for men at risk.
Middle-aged and older men with low testosterone demonstrate reduced mitochondrial respiration and decreased SIRT3 expression in vascular endothelial cells, indicating accelerated vascular aging through impaired oxidative stress regulation. This mechanism links testosterone deficiency directly to cardiovascular disease risk through mitochondrial dysfunction.
Loss of chromosome Y in male leukocytes, detected in nearly 9% of cells in older men, produces cell-type-specific immune dysfunction characterized by altered monocyte differentiation and aberrant X-chromosome inactivation patterns. These molecular changes associate with increased risk for cardiovascular disease and cancer, suggesting LOY represents a meaningful driver of age-related immune decline in men rather than a neutral age-related marker.
Catalyst Precision Health launches an integrated model combining in-home testing, physician house calls, and continuous personalized care for men's longevity, addressing fragmentation in the current market where health data remains scattered across disconnected providers and platforms.
Aging science built primarily on male biology has systematically misunderstood female physiology, leading to ineffective or harmful optimization strategies for women. A female-centered approach recognizes that women's hormonal cycles are rhythmic rather than erratic, and that sex-based differences in metabolism, hormone production, and social bonding represent distinct biological advantages requiring tailored intervention.
PDE5 inhibitors, established drugs for erectile dysfunction, are attracting early interest in longevity medicine for their capacity to improve vascular function and tissue resilience through nitric oxide signaling—not by targeting root causes of aging, but by supporting system performance under the stress of accumulated damage.
Acorn Biolabs has initiated a randomized, controlled trial of YOU, an autologous secretome derived from hair follicle stem cells, to treat androgenic alopecia. The study will measure changes in hair density, thickness, and patient outcomes against placebo, establishing whether personalized regenerative approaches offer clinically meaningful advantages over existing pharmacologic treatments.
